Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to be driven by autoimmune processes. Because vitiligo affects patients’ appearance, the disease burden is high. Until 2022, no therapies were approved to treat it; topical steroids or other immunomodulators alone or in combination with narrow-band UVB to induce repigmentation were the mainstay treatments for vitiligo patients. However, these treatments confer only modest clinical benefit and can have troublesome side effects. However, the FDA’s July 2022 approval of Incyte’s Opzelura (topical ruxolitinib) gives patients the first approved pharmacological treatment for repigmentation in vitiligo; the FDA approved Opzelura cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 or older. Multiple therapies with diverse mechanisms of action are in development to treat vitiligo and, if efficacious, stand to capitalize on the immense unmet need for effective therapies in this space.
Executive Insights provides indication-specific market intelligence with world-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography United States
Primary research 3 KOL interviews in February to March 2023
Key companies covered Incyte, Pfizer, Clinuvel
Key drugs covered Opzelura, ritlecitinib, afamelanotide, INCB-054707